Research programme: anticancer therapeutics - Exelixis
Alternative Names: Antibody-drug conjugates - Exelixis; STING ADC - Exelixis; STING based antibody-drug conjugates - ExelixisLatest Information Update: 03 Aug 2022
At a glance
- Originator Exelixis
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer